Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified Therapy for Adult Acute Lymphocytic Leukemia (O5/93)
NCT00002531Phase 2Unknown
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jan 1993
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide, cytarabine, mitoxantrone and methotrexate in acute lymphoblastic leukemia (ALL) (6 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Complete Remission Rate, Duration of Remission up to 4 years and 1 more. Status: unknown.
02
Drugs
cyclophosphamidecytarabinemitoxantronemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00002531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002531.